scholarly journals 75P Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib + checkpoint inhibitor (CPI) therapy

2021 ◽  
Vol 32 ◽  
pp. S1404-S1405
Author(s):  
L. Huynh ◽  
S.S. Du ◽  
R. Chang ◽  
S. Pi ◽  
S. Sundaresan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adverse Event ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitor ◽  
Advanced Renal Cell Carcinoma ◽  
First Line ◽  
Therapy Management ◽  
Resolution Improvement

The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study

2018 ◽  
Vol 24 (4) ◽  
pp. 411-419 ◽  
Author(s):  
Aristotelis Bamias ◽  
Vasilios Karavasilis ◽  
Nikolaos Gavalas ◽  
Kimon Tzannis ◽  
Epaminontas Samantas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
First Line ◽  
Anti Vegf

scholarly journals VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

2012 ◽  
Vol 108 (5) ◽  
pp. 1126-1132 ◽  
Author(s):  
M Scartozzi ◽  
M Bianconi ◽  
L Faloppi ◽  
C Loretelli ◽  
A Bittoni ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
First Line

scholarly journals Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

2020 ◽  
Vol 36 (9) ◽  
pp. 1507-1517
Author(s):  
Arielle G. Bensimon ◽  
Yichen Zhong ◽  
Umang Swami ◽  
Allison Briggs ◽  
Joshua Young ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document